Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Operating Leases (2023 - 2025)

Kura Oncology (KURA) has disclosed Operating Leases for 3 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 82.45% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 million, a 82.45% increase, with the full-year FY2025 number at $9.5 million, up 82.45% from a year prior.
  • Operating Leases was $9.5 million for Q4 2025 at Kura Oncology, up from $8.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $9.5 million in Q4 2025 to a low of $1.5 million in Q2 2023.
  • A 3-year average of $6.1 million and a median of $6.3 million in 2023 define the central range for Operating Leases.
  • Biggest YoY gain for Operating Leases was 301.58% in 2024; the steepest drop was 18.42% in 2024.
  • Kura Oncology's Operating Leases stood at $6.4 million in 2023, then decreased by 18.42% to $5.2 million in 2024, then surged by 82.45% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Operating Leases are $9.5 million (Q4 2025), $8.4 million (Q3 2025), and $8.2 million (Q2 2025).